Neutrophilia-Inducing Deferoxamine in Mice Infected with Staphylococcus aureus


The ability to sequester iron is a primary defense mechanism against bacterial infection. Iron chelation therapy has been considered as a possible treatment for various infectious diseases. S. aureus isolated from neonatal septicemia were used to study the effect of deferoxamine and sub-minimal inhibitory concentration of gentamicine on some virulence factors of this isolates. Also an experimental sepsis was inducted in mice and treated with gentamicin and deferoxamine. The expression of virulence factor (alpha-hemolysin, beta-hemolysin, delta-hemolysin, coagulase, and DNase) by Staphylococcus aureus isolates was significantly decreased (p < 0.05) after exposure to DFO and/or gentamicin. The data of the present study showed that using of DFO led to significant decrease (p < 0.05) in the mortality rate of mice infected with S. aureus. In a murine model of S. aureus sepsis, deferoxamine treatment had an additional effect on survival and bacterial eradication from the organs of septicemic mice. In vitro exposure of S. aureus isolated to gentamicin and deferoxamine led to a decrease in the production of some virulence factors by these isolates.

Share and Cite:

M. Al-Jebouri and N. Jafar, "Neutrophilia-Inducing Deferoxamine in Mice Infected with Staphylococcus aureus," Open Journal of Pathology, Vol. 3 No. 2, 2013, pp. 99-106. doi: 10.4236/ojpathology.2013.32018.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] V. R. Gordeuk, P. E. Thuma, G. M. Brittenham, et al., “Iron Chelation as a Chemotherapeutic Strategy for Falciparum Malaria,” The American Journal of Tropical Medicine and Hygiene, Vol. 4, No. 4, 1993, pp. 193-197.
[2] R. C. Hider and Z. Liu, “The Treatment of Malaria with Iron Chelators,” Journal of Pharmacy and Pharmacology, Vol. 49, No. 1, 1997, pp. 59-64. doi:10.1111/j.2042-7158.1997.tb06162.x
[3] R. S. Bhimani, Y. Vendrov and P. Furmanski, “Influence of Lactoferrin Feeding and Injection against Systemic Staphylococcal Infections in Mice,” Journal of Applied Microbiology, Vol. 86, Vol. 1, 1999, pp. 135-144.
[4] S. Baveye, E. Elass, J. Mazurier, et al., “A Multifunctional Glycoprotein Involved in the Modulation of the Inflammatory Process,” Clinical Chemistry and Laboratory Medicine, Vol. 37, No. 3, 1999, pp. 281-286. doi:10.1515/CCLM.1999.049
[5] S. H. Hartzen, N. Frimodt-Moller and V. F. Thomsen, “The Antibacterial Activity of a Siderophore. 2. The Influence of Deferoxamine Alone and Combined with Ascorbic Acid on the Activity of Antibiotics against Staphylococcus aureus,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, Vol. 99, No. 10, 1991, pp. 879-886. doi:10.1111/j.1699-0463.1991.tb01274.x
[6] B. V. Asbeck, J. J. Marx, A. Struyvenberg, et al., “Deferoxamine Enhances Phagocytic Function of Human Polymorphonuclear Leukocytes,” Blood, Vol. 63, No. 3, 1984, pp. 714-720.
[7] A. Emine, G. Suveyda, C. Ozlem, et al., “Effect of Granulocyte Colony-Stimulating Factor in Experimental Methicillin Resistant Staphylococcus aureus Sepsis,” BMC Infectious Diseases, Vol. 4, No. 2, 2004, p. 43.
[8] C. G. Gemmell and C. W. Ford, “Virulence Factor Expression by Gram-Positive Cocci Exposed to Subinhibitory Concentrations of Linezolid,” Journal of Antimicrobial Chemotherapy, Vol. 50, No. 2, 2002, pp. 665-672. doi:10.1093/jac/dkf192
[9] V. Shery, T. Yue and A. James, “Contrasting Sensitivities of Escherichia coli Aconitases A and B to Oxidation and Iron Depletion,” Journal of Bacteriology, Vol. 185, No. 1, 2003, pp. 221-230. doi:10.1128/JB.185.1.221-230.2003
[10] G. A. Somerville, M. S. Chaussee, C. I. Morgan, et al., “Staphylococcus aureus Aconitase Inactivation Unexpectedly Inhibits Post-Exponential-Phase Growth and Enhances Stationary-Phase Survival,” Infection and Immunity, Vol. 70, No. 11, 2002, pp. 6373-6382. doi:10.1128/IAI.70.11.6373-6382.2002
[11] G. A. Somerville, S. B. Beres, L. R. Fitzgerald, et al., “In Vitro Serial Passage of Staphylococcus aureus: Changes in Physiology, Virulence Factor Production, and Agr Nucleotide Sequence,” Journal of Bacteriology, Vol. 185, No. 5, 2002, pp. 1430-1437. doi:10.1128/JB.184.5.1430-1437.2002
[12] G. Kahlmeter, “Non-Betalactam Antibiotics—Clinical MIC-Values and Species-Related MIC-Breakpoints. European Committee on Antimicrobial Susceptibility Testing (EU-CAST),” 2005.
[13] C. G. Gemmell, P. K. Peterson, D. Schmeling, et al., “Potentiation of Opsonization and Phagocytosis of Streptococcus pyogenes Following Growth in the Presence of Clindamycin,” Journal of Clinical Investigation, Vol. 67, No. 3, 1981, pp. 1249-1256. doi:10.1172/JCI110152
[14] A. M. Shibl and I. A. Al-Sowaygh, “Differential Inhibition of Bacterial Growth and Hemolysin Production by Lincosamide Antibiotics,” Journal of Bacteriology, Vol. 137, No. 5, 1979, pp. 1022-1023.
[15] S. E. Unkles and C. G. Gemmell, “Effect of Clindamycin, Erythromycin, Lincomycin, and Tetracycline on Growth and Extracellular Lipase Production by Propionibacteria in Vitro,” Antimicrobial Agents and Chemotherapy, Vol. 21, No. 1, 1982, pp. 39-43. doi:10.1128/AAC.21.1.39
[16] A. M. Shibl and I. A. Al-Sowaygh, “Antibiotic Inhibition of Protease Production by Pseudomonas aeruginosa,” Journal of Medical Microbiology, Vol. 13, No. 2, 1980, pp. 345-348. doi:10.1099/00222615-13-2-345
[17] A. M. Shibl and C. G. Gemmell, “ Effect of Four Antibiotics on Haemolysin Production and Adherence to Human Uroepithelial Cells by Escherichia coli,” Journal of Medical Microbiology, Vol. 16, No. 3, 1983, pp. 341-349. doi:10.1099/00222615-16-3-341
[18] S. Herbert, P. Barry and R. P. Novick, “Subinhibitory Clindamycin Differentially Inhibits Transcription of Exoprotein Genes in Staphylococcus aureus,” Infection and Immunity, Vol. 69, No. 5, 2001, pp. 2996-3003. doi:10.1128/IAI.69.5.2996-3003.2001
[19] M. M. Al-Jebouri and N. A. Jafar, “Neutroplilia-Induced Deferoxamine in Mice Infected with Staphylococcus aureus,” International Symposium, Abstracts, The Neutrophil in Immunity, Quebec, 2012, p. 130.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.